Description: Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
Home Page: www.roche.com
Grenzacherstrasse 124
Basel,
4058
Switzerland
Phone:
41 61 688 11 11
Officers
Name | Title |
---|---|
Dr. Severin Schwan Ph.D. | Executive Chairman |
Dr. Thomas Schinecker | Chief Executive Officer |
Dr. Alan Hippe | Chief Financial & Information Officer |
Dr. Bruno Eschli | Head of Investor Relations |
Ms. Claudia Bockstiegel | General Counsel |
Ms. Pascale Schmidt | Chief Compliance Officer |
Ms. Barbara Schadler | Head of Group Communications |
Ms. Cristina A. Wilbur | Chief People Officer |
Dr. Nicolas Dunant | Head of Group Media Relations |
Mr. Boris L. Zaitra | Head of Corporate Business Development |
Exchange: MX
Country: MX : Mexico
Currency: Mexican Peso (₱)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Pharmaceuticals |
GIC Sub-Industry: | Pharmaceuticals |
Forward PE: | 12.21 |
---|---|
Trailing PE: | 19.4153 |
Price-to-Book MRQ: | 7.0707 |
Price-to-Sales TTM: | 78.4736 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 103605 |